Why the study?
Nimodipine is recommended to prevent delayed cerebral ischemia in patients with spontaneous SAH, but the hemodynamic side effects of different formulations required evaluation.
Does the formulation of nimodipine (IV vs PO) affect the incidence of significant blood pressure drops in patients with spontaneous subarachnoid hemorrhage?
Comparison
Intravenous vs per os prophylactic nimodipine
Design
Observational cohort study
Follow-up
First hour after continuous IV nimodipine initiation or PO nimodipine application
Authors
Loading...
Intensified BP monitoring may be warranted with nimodipine in SAH; leaves open impact on outcomes.
Does the formulation of nimodipine (IV vs PO) affect the incidence of significant blood pressure drops in patients with spontaneous subarachnoid hemorrhage?
Intravenous nimodipine causes significant systolic blood pressure drops in nearly a third of SAH patients, necessitating careful hemodynamic monitoring and potential vasopressor support compared to oral administration.
Rass et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: